期刊文献+

早期非小细胞肺癌患者血清巨噬细胞抑制因子-1、趋化素与临床病理特征及预后的关系 被引量:8

Relationship between Serum Macrophage Inhibitor-1, Chemokine and Clinicopathological Features and Prognosis in Patients with Early Non-small Cell Lung Cancer
原文传递
导出
摘要 目的:探讨早期非小细胞肺癌(NSCLC)患者血清巨噬细胞抑制因子-1(MIC-1)、趋化素(chemerin)水平与临床病理特征及预后的关系。方法:选择72例NSCLC患者(NSCLC组)、53例肺良性疾病患者(良性组)、50例体检健康人群(对照组),分别检测血清MIC-1、chemerin水平,分析血清MIC-1、chemerin水平与NSCLC患者临床病理参数的关系。Kaplan-Meier法分析不同血清MIC-1、chemerin水平NSCLC患者生存时间的差异,COX比例风险回归分析血清MIC-1、chemerin水平与NSCLC患者预后的关系。结果:NSCLC组患者血清MIC-1、chemerin水平高于良性组和对照组(P<0.05)。血清MIC-1水平与NSCLC患者年龄、目前吸烟、肿瘤直径、TNM分期、分化程度、复发或转移、生存状态有关(P<0.05),chemerin水平与NSCLC患者目前吸烟、TNM分期、复发或转移、生存状态有关(P<0.05)。高MIC-1水平患者生存率低于低MIC-1水平患者(P<0.05),高chemerin水平患者生存率低于低chemerin水平患者(P<0.05)。COX比例风险回归分析结果显示:血清MIC-1、chemerin、TNM分期与NSCLC不良预后独立相关。结论:血清MIC-1、chemerin水平与NSCLC患者部分临床病理参数和预后相关,可作为早期NSCLC患者预后预测的潜在指标。 Objective: To investigate the relationship between serum level of macrophage inhibitory factor-1(MIC-1) and chemerin and clinicopathological features and prognosis in patients with early non-small cell lung cancer(NSCLC). Methods: 72 patients with NSCLC(NSCLC group), 53 patients with benign pulmonary diseases(benign group) and 50 healthy people(control group) were selected. Serum MIC-1 and chemerin levels were detected respectively. The relationship between serum MIC-1 and chemerin levels and clinicopathological parameters of NSCLC patients was analyzed. The survival time of NSCLC patients with different serum levels of MIC-1 and Chemerin was analyzed by Kaplan-Meier method. The relationship between serum levels of MIC-1 and chemerin and the prognosis of NSCLC patients was analyzed by COX proportional risk regression. Results: The serum MIC-1 and chemerin levels in NSCLC group were higher than those in benign group(P<0.05). Serum MIC-1 level was correlated with age, current smoking, tumor diameter, TNM stage, differentiation degree, recurrence or metastasis, survival status of NSCLC patients(P<0.05), and chemerin level was correlated with current smoking, TNM stage, recurrence or metastasis and survival status of NSCLC patients(P<0.05). The survival rate of patients with high MIC-1 level was lower than that of patients with low MIC-1 level(P<0.05), and survival rate of patients with high chemerin level was lower than that of patients with low chemerin level(P<0.05). COX proportional risk regression analysis showed that serum MIC-1, chemerin and TNM stage levels were independently associated with poor prognosis of NSCLC. Conclusion: Serum MIC-1 and chemerin levels are correlated with some clinicopathological parameters and prognosis of NSCLC patients, and they can be used as potential prognostic indicators for early NSCLC patients.
作者 吕蒙 王昂 王杰 鄢文 尤长宣 LV Meng;WANG Ang;WANG Jie;YAN Wen;YOU Chang-xuan(Department of Oncology,Huiqiao Medical Center,Nanfang Hospital of Southern Medical University,Guangzhou,Guangdong,510000,China;First Ward of Oncology,Second People's Hospital of Guangdong Province,Guangzhou,Guangdong,510000,China;Department of Radiotherapy,Second People's Hospital of Guangdong Province,Guangzhou,Guangdong,510000,China)
出处 《现代生物医学进展》 CAS 2019年第21期4103-4107,共5页 Progress in Modern Biomedicine
基金 广东省科技计划项目(2017B090901067)
关键词 非小细胞肺癌 巨噬细胞抑制因子-1 趋化素 病理特征 预后 Non-small cell lung cancer Macrophage inhibitor-1 Chemerin Pathological characteristics Prognosis
  • 相关文献

参考文献11

二级参考文献77

  • 1李勇,张湘茹,孙燕.小细胞肺癌患者预后的多因素分析[J].中国肺癌杂志,2006,9(6):525-529. 被引量:19
  • 2李立明.流行病学[M].北京:人民卫生出版社,2007.454.
  • 3中华人民共和国卫生部疾病控制司.中国成人超重和肥胖症预防控制指南[M],北京:人民卫生出版社,2006,1-20.
  • 4Rubin P,Hansen JT.肿瘤TNM分期图谱[M].王瑛,译.天津:天津科技翻译出版公司,2011:395-400.
  • 5Jernal A, Siegel R, Ward E, et al. Cancer statistics, 2008[J]. CA Cancer J Clin, 2008,58:71 - 96.
  • 6Elias AD. Small cell lung cancer: state of- the- art therapy in 1996 [J]. Chest, 1997,112:2515 -2585.
  • 7World Health Organization. WHO handbook for reporting results of can cer treatment (WHO Offdet Publication No. 48 ) [ R ]. Geneva, Switzerland: World Health Organization, 1979.
  • 8International Agency for Research on Cancer. IARC Biennial Report 2000/2001[M]. Lyou: IACR,2001 : 13 - 14.
  • 9Govindan R, Page N, Morgensztem D, et al. Changing epidemiology of small cell lung cancer in the United States over the last 30 years: anal- ysis of the surveillance, epidemioiogic, and end results database[J ]. J Clin Oncol, 2006,24:4s39 - 44.
  • 10Wheatley - Price P, Ma C, Ashcroft LF, et al. The strength of female sex as a prognostic factor in small cell lung cancer: a pooled analysis of che- mothe rapy trials from the Manchester Lung Group and Medical Re- search Council Clinical Trials Unit[J ]. Ann Oncol, 2010,21 (2):232 - 237.

共引文献57

同被引文献61

引证文献8

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部